Health secretary Jeremy Hunt

Price tags on medicine packs a “headline grabbing gimmick”

August 7, 2015
Manufacturing and Production, Medical Communications Drug pricing, Jeremy Hunt, NHS, adherence, compliance

Plans to include a price tag on prescription medicines in England worth more than £20 have been dismissed as a …

Pharma companies ‘using more in-house digital teams’

August 7, 2015
Medical Communications Med Comms, advertising, agencies, branding, communications, medical communications, social media

Fewer pharma companies are moving away from using external agencies for their digital marketing, a US survey has found.A study …

MyHeart Counts ResearchKit app

First Apple ResearchKit app launches in the UK

August 7, 2015
Medical Communications Apple, clinical trial, heart disease, researchkit, strokes

The first ResearchKit app to be made available to users outside of the US has launched in the UK. The …

bedrock

Bedrock Healthcare Communications makes new hires

August 6, 2015
Medical Communications Bedrock Healthcare Communications

Bedrock Healthcare Communications has made several new additions to the team.Sam Simpson joins as account director, Francesca Worthington as account …

Pfizer and Flynn rapped for overcharging on anti-epilepsy drug

August 6, 2015
Manufacturing and Production, Sales and Marketing CMA, Drug pricing, Flynn Pharma, Pfizer, competitions markets authority, epilepsy, generics, phenytoin, pricing

Pharma firms Pfizer and Flynn Pharma have been accused by the UK’s competition watchdog of charging ‘excessive and unfair’ prices …

MedImmune building Cambridge

MedImmune and Mirati to partner on lung cancer combo

August 6, 2015
Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat

MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …

astrazeneca image

AstraZeneca buys rights to Heptares experimental cancer treatment

August 6, 2015
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, HTL-1071, immuno-oncology

AstraZeneca has entered into a licensing agreement with Heptares for the global rights to the experimental cancer treatment HTL-1071. The …

NICE

NICE demands more evidence of Lynparza benefits

August 6, 2015
Sales and Marketing AstraZeneca, NICE, lynparza, ovarian cancer

AstraZeneca must provide a “robust estimate of the cost effectiveness” of its ovarian cancer treatment Lynparza, or risk being rejected …

pharma sales graph

Pharma industry worth more than $1 trillion – and growing

August 5, 2015
Sales and Marketing pharma sales, research and development

Global pharmaceutical sales are set to continue rising beyond the $1 trillion milestone reached in 2014, according to newly-released figures. …

Shire building

Shire goes public with rejected $30bn Baxalta bid

August 5, 2015
Research and Development, Sales and Marketing Baxalta, Shire, acquisitions, baxter, mergers, rare disease

Shire has confirmed that it made an all-share $30 billion offer to buy Baxalta last month, citing ’a strong strategic …

Lilly set for Cymbalta lawsuit showdown

August 5, 2015
Research and Development cymbalta, duloxetine, lawsuit, lilly

Lilly is contesting the first in a series of lawsuits brought by patients who say the company failed to inform …

Spritam

First 3D-printed drug approved by FDA

August 4, 2015
Manufacturing and Production, Research and Development 3d printing, FDA, manufacturing, production

The world of medicine saw a new pharma milestone this week, with the first approval by the FDA of a …

Toujeo pen

Sanofi launches new insulin Toujeo in the UK

August 4, 2015
Manufacturing and Production, Sales and Marketing Lantus, Sanofi, biosimilars, diabetes, hypoglycaemia, insulin, toujeo

Sanofi’s new insulin Toujeo is now available for clinicians to prescribe in the UK. The French firm is looking to …

Hospira logo

Hospira in major US ketorolac recall

August 4, 2015

Hospira is being dogged with manufacturing problems that have led to the recall of millions of vials of its painkilling …

Teva image

Teva buys majority stake in genomic analysis firm

August 4, 2015
Manufacturing and Production, Research and Development, Sales and Marketing CNS, Immuneering, Teva, central nervous system, genetic analysis

Teva has agreed to by a 51% equity share of genomic-analysis company Immuneering to advance treatments for diseases of the …

Shire building

Shire in $300m Foresight acquisition

August 4, 2015
Manufacturing and Production, Research and Development, Sales and Marketing FST-100, Foresight Biotherapeutics, Shire, conjunctivitis, dry eye, lifitegrast, pink eye

Shire has acquired Foresight Biotherapeutics for $300 million, as it looks to build its presence in eye diseases. The acquisition …

CSL completes $275m Novartis vaccines acquisition

August 3, 2015
Manufacturing and Production, Sales and Marketing CSL, Novartis, acquisitions, asset swap, vaccines

CSL Limited has finalised its transaction to acquire Novartis’s global influenza vaccine business for $275 million. The move means Novartis …

AZ sign

AstraZeneca and Isis Pharma in $65m drugs collaboration

August 3, 2015
Manufacturing and Production, Research and Development AstraZeneca, Isis Pharma, Isis Pharmaceuticals, antisense, drug R&D

Isis Pharmaceuticals and AstraZeneca have announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal …

profgrantweb

Sir Malcolm Grant reappointed as NHS England chair

August 3, 2015

Professor Sir Malcolm Grant has been re-appointed as Chair of NHS England from 31 October 2015 for a further three …

Lee Heeson

Working Life: Celgene’s Lee Heeson

August 3, 2015
Medical Communications, Sales and Marketing Celgene, Lee Heeson

How did you find your way into your current role?My career has progressed from ‘carrying the bag’ for GlaxoSmithKline in …

The Gateway to Local Adoption Series

Latest content